

Disagreement Between Theoretical and Actual Phorcides Outcomes: Is Phorcides Inferior to Treating on the Manifest Refraction? [Letter]

This article was published in the following Dove Press journal:
Clinical Ophthalmology

Avi Wallerstein^{1,2,*}
Mathieu Gauvin^{1,2,*}

¹Department of Ophthalmology and Visual Sciences, McGill University, Montreal, QC, Canada; ²Department of Research & Development, LASIK MD, Montreal, QC, Canada

*These authors contributed equally to this work

Dear Editor

We read with interest “Topography-Guided Refractive Astigmatism Outcomes: Predictions Comparing Three Different Programming Methods.”¹ In the Manifest group, the calculated theoretical outcomes revealed an unexpectedly elevated postoperative refractive astigmatism average error of 0.56 ± 0.22 D.¹ This large amount of theoretical postoperative cylinder was not replicated in a recent real-world clinical study by the same authors, comparing actual topography-guided LASIK outcomes in Phorcides versus manifest-treated eyes.² The reported empirical postoperative astigmatism error average in the Manifest group was as low as 0.15 D, fourfold better than that reported in the current theoretical outcomes study.¹

In the current theoretical study,¹ only 56% of Manifest eyes showed a refractive astigmatism error of 0.50 D or less, compared to 96% of eyes in the real-world clinical study.² In addition, 15% of Manifest eyes exhibited an “outlier” postoperative refractive astigmatism error of 1.00 D or greater, compared to only 1% in the real-world study.²

The real-world clinical study further revealed that the refractive astigmatism accuracy was statistically inferior in Phorcides eyes that were matched to the FDA study criteria.² Surprisingly, this inferior postoperative SEQ and refractive astigmatism accuracy with Phorcides was accompanied with a significantly better rate of postoperative 20/16 UDVA.² This clinical finding of having superior visual acuity despite inferior refractive accuracy is atypical and inconsistent with current laser vision correction literature.³

These conflicting results highlight that the current theoretical outcomes study¹ does not reflect real-world manifest-treated eyes outcomes, where manifest eyes are superior to Phorcides eyes in terms of refractive astigmatism and SEQ accuracy.² What could explain the significant disagreement between these poor theoretical¹ versus excellent real-world² manifest-treatment outcomes?

In the theoretical study, vector analyses of postoperative cylindrical errors and programmed cylindrical laser treatment values were used to calculate expected outcomes that in theory may have been obtained using either Manifest, LYRA or Phorcides treatment. Using this methodology, a successful plano postoperative eye treated using the Contoura-measured anterior corneal astigmatism (LYRA protocol) with 1.00 D of difference between manifest and topographical cylinder

Correspondence: Avi Wallerstein
MD Level, 1250 Rene-Levesque Blvd W,
Montreal, QC H3B 4W8, Canada
Tel +1 514-908-9888 Ext 2273
Email awallerstein@lasikmd.com

preoperatively, leads to a theoretical postoperative refractive astigmatism error of 1.00 D in the Manifest group. Such theoretical assumptions are invalid, since published clinical outcomes studies do not necessarily reveal differences in postoperative refractive astigmatism errors between treating the manifest astigmatism, the topographical astigmatism, or the vector planning approach.^{2,4,5}

Given that most eyes (~75%) were treated using the LYRA protocol prior to such theoretical calculations, and since the preoperative difference between refractive and anterior corneal astigmatism was large, with 73% of eyes having a difference greater than 0.50 D,¹ the Manifest group was significantly disadvantaged by the study design. This treatment bias, where most eyes were treated using the LYRA protocol and not the manifest, led to an over-estimated theoretical refractive astigmatism error in the Manifest group. This explains why the real-world clinical study outcomes do not reflect the current theoretical study outcomes.

In summary, the authors' statement that Phoricides and LYRA "will produce outcomes that are superior to those obtained when the Manifest refraction is entered as the treatment" is scientifically flawed considering: the bias related to treatment type being mostly LYRA, the selection bias introduced from doctors choosing treatment type with undetermined criteria and nomograms, and the same author real-world outcomes study showing superior refractive accuracy outcomes in Manifest eyes compared to Phoricides eyes. A review of over 150,000 of our

topography-guided treated eyes, where accurate manifest refraction data and an advanced big data nomogram were used, demonstrates that refractive outcomes of manifest-treated eyes are better than Phoricides,³ and LYRA.⁵

Disclosure

The authors have no conflict to disclose and no financial interest in the subject matter or materials presented herein in this letter to editor. The authors equally contributed to this letter.

References

1. Stulting RD, Durrie DS, Potvin RJ, et al. Topography-guided refractive astigmatism outcomes: predictions comparing three different programming methods. *Clin Ophthalmol.* 2020;14:1091–1100. doi:10.2147/OPTH.S244079
2. Lobanoff M, Stonecipher K, Tooma T, Wexler S, Potvin R. Clinical outcomes after topography-guided LASIK: comparing results based on a new topography analysis algorithm to those based on the manifest refraction. *J Cataract Refract Surg.* 2020. doi:10.1097/j.jcrs.000000000000176
3. Wallerstein A, Gauvin M. Is phoricides more likely to give better vision than treating the manifest refraction? *J Cataract Refract Surg.* 2020;46(10):1451–1452.
4. Arbelaez MC, Alpíns N, Verma S, Stamatelatos G, Arbelaez JG, Arba-Mosquera S. Clinical outcomes of laser in situ keratomileusis with an aberration-neutral profile centered on the corneal vertex comparing vector planning with manifest refraction planning for the treatment of myopic astigmatism. *J Cataract Refract Surg.* 2017;43(12):1504–1514. doi:10.1016/j.jcrs.2017.07.039
5. Wallerstein A, Gauvin M, Qi SR, Bashour M, Cohen M. Primary topography-guided LASIK: treating manifest refractive astigmatism versus topography-measured anterior corneal astigmatism. *J Refract Surg.* 2019;35:15–23. doi:10.3928/1081597X-20181113-01

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Ophthalmology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Ophthalmology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed

Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress